Search Results Search Sort by RelevanceMost Recent Medical Education Dec 2020 How Educators Can Help Prevent False Brain Death Diagnoses Farah Fourcand, MD and Diana M. Barratt, MD, MPH For many physicians, lack of understanding about brain death leads to confusion and muddles interactions with patients’ loved ones at the end of life. AMA J Ethics. 2020;22(12):E1010-1018. doi: 10.1001/amajethics.2020.1010. Viewpoint May 2022 Reimagining Roles of Dietary Supplements in Psychiatric Care Katherine Wu, MD and Erik Messamore, MD, PhD Government-supported review and safety monitoring is needed for dietary supplements’ use in the care of patients with mental illness. AMA J Ethics. 2022;24(5):E437-442. doi: 10.1001/amajethics.2022.437. Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.
Medical Education Dec 2020 How Educators Can Help Prevent False Brain Death Diagnoses Farah Fourcand, MD and Diana M. Barratt, MD, MPH For many physicians, lack of understanding about brain death leads to confusion and muddles interactions with patients’ loved ones at the end of life. AMA J Ethics. 2020;22(12):E1010-1018. doi: 10.1001/amajethics.2020.1010.
Viewpoint May 2022 Reimagining Roles of Dietary Supplements in Psychiatric Care Katherine Wu, MD and Erik Messamore, MD, PhD Government-supported review and safety monitoring is needed for dietary supplements’ use in the care of patients with mental illness. AMA J Ethics. 2022;24(5):E437-442. doi: 10.1001/amajethics.2022.437.
Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.